This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synageva BioPharma™ Highlights Sebelipase Alfa And LAL Deficiency Data At The Lysosomal Disease Network (LDN) WORLD Symposium™

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced sebelipase alfa and lysosomal acid lipase deficiency (LAL Deficiency) data from oral and poster presentations at the LDN WORLD Symposium being held February 11-13 in San Diego, California.

Initial results with sebelipase alfa from an ongoing Phase 2/3 trial in infants with LAL Deficiency

As part of an oral presentation, Vassili Valayannopoulos, MD, Clinical Lead of the Lysosomal Storage Disease Clinic at Necker-Enfants Malades Hospital, Paris, France, presented initial results from the ongoing Phase 2/3 trial with sebelipase alfa in infants with LAL Deficiency. Data from nine infants enrolled in the trial as of January 2014 were presented at the meeting. The median age of infants at first infusion with sebelipase alfa was 3.0 months. Infants continuing in the trial demonstrate improvements in weight gain and other disease-related abnormalities after starting treatment with weekly infusions of sebelipase alfa (1-3 mg/kg). Six infants continue to receive treatment with sebelipase alfa, including three infants who met the primary endpoint of survival at 12 months of age and three infants who continue on treatment beyond six months of age. Two infants died shortly after starting the study due to rapidly progressive disease not related to the study drug (sebelipase alfa). One infant died shortly after starting the study due to a non-study related procedure and also unrelated to sebelipase alfa.

Adverse events with sebelipase alfa were mostly mild to moderate. Serious adverse events were mainly related to central line infections or hospitalizations for treatment with antibiotics. One patient experienced three related serious adverse events that included fever, malaise, and tachycardia developed during the infusion of sebelipase alfa. Four infants developed anti-drug antibodies and all four continue on infusions with sebelipase alfa at 3 mg/kg.

"Sebelipase alfa represents a potentially dramatic breakthrough for infants with LAL Deficiency who often die without treatment, usually before six months of age,” said Dr. Valayannopoulos. “As an enzyme replacement therapy, sebelipase alfa addresses the underlying cause of this rapidly progressive and often fatal disease and we are excited to continue dosing these infants as part of the ongoing Phase 2/3 clinical trial.”

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs